Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add ‐on mirabegron therapy to solifenacin (BESIDE)

ConclusionThe comparable frequency of CV‐related TEAEs, changes in vital signs and ECG parameters indicates no synergistic effect on CV safety outcomes when mirabegron and solifenacin are combined.
Source: International Journal of Clinical Practice - Category: Internal Medicine Authors: Tags: ORIGINAL PAPER Source Type: research

Related Links:

Bioelectronic medicine could be one of healthcare’s biggest secrets. The space is filled with applications – but many aren’t mainstream yet. A panel titled “ Bioelectronic Medicine: Redefining Medical Treatment,” will be held Tuesday, February 11, from 2:05 to 3:00 p.m. in Room 210A at MD&M West Anaheim to discuss the space and how it could impact healthcare. While there have been some significant movements in that time – perhaps one of the greatest has developments has been GlaxoSmithKline teaming up with Verily Lif...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Electronics Source Type: news
Wrapping up this year and looking back on the particularly interesting developments in medical technology, we at Medgadget are impressed and very excited about the future. We’re lucky to cover one of the most innovative fields of research and o...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Source Type: blogs
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us. So without further ado, here are the 20 companies that made the cut: 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Publication date: Available online 18 October 2019Source: European UrologyAuthor(s): Christopher R. Chapple, Francisco Cruz, Linda Cardozo, David Staskin, Sender Herschorn, Nurul Choudhury, Matthias Stoelzel, John Heesakkers, Emad SiddiquiAbstractBackgroundMirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms.ObjectiveTo summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms.Design, setting, and participantsPooled data analysed from 10 phase 2–4, double-blind, 12-wk mirabegron monotherapy studies in adults with OAB who h...
Source: European Urology - Category: Urology & Nephrology Source Type: research
DiscussionIntravesical BCG is a standard adjuvant treatment for carcinoma in situ with 75% induced cystitis as a local side effect. The International Bladder Cancer Group’s recommendation for BCG cystitis included many agents, these treatment options had very limited outcomes. The existence of paraganglioma in the female genital tract described rarely
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Abstract INTRODUCTION: Lower urinary tract symptoms (LUTS) have a strong effect on socio-economic and individual quality of life. The aim of the present study was to investigate the prevalence of LUTS in an Asian population. METHODS: A telephone survey of individuals aged ≥40 years and of Chinese ethnicity was conducted. The survey included basic demographics, medical and health history, drinking habits, International Prostate Symptom Score, overactive bladder symptom score, Patient Health Questionnaire (PHQ-9) score, and Short Form (SF)-12v2 score. RESULTS: From March to May 2017, 17 338 calls were m...
Source: Hong Kong Med J - Category: General Medicine Authors: Tags: Hong Kong Med J Source Type: research
AbstractIntroduction and hypothesisMultiple publications have demonstrated the efficacy of percutaneous tibial nerve stimulation (PTNS) for overactive bladder syndrome (OAB). However, patient characteristics associated with successful treatment have not been well established.The aim of this study was to identify prognostic factors for successful PTNS treatment.MethodsThis was a retrospective chart review of women who underwent PTNS therapy for OAB between January 2011 –Decemeber 2017. Treatment success was defined by subjective improvement according to patient self-report and objective bladder diary parameters includ...
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Conclusions: WML is associated with age and is common in the elderly population. Mild WML is subclinical, with no obvious neurological and urinary symptoms. Our cohort did not demonstrate a relationship between WML and lower urinary tract symptoms. PMID: 30155303 [PubMed]
Source: Journal of Aging Research - Category: Geriatrics Tags: J Aging Res Source Type: research
ConclusionsThe relief of key OAB symptoms produced by mirabegron 50 mg is significantly better than placebo, and similar to a range of common antimuscarinics, with the benefit of significantly fewer bothersome anticholinergic side effects such as dry mouth. Combination treatment of solifenacin 5 mg plus mirabegron 25 or 50 mg appears to provide an efficacy benefit compared with mirabegron 50 mg, with the expected side effects of individual antimuscarinics.Patient summaryThis study assessed the efficacy and tolerability of different drug treatments for OAB. Mirabegron 50 mg was as effective as antim...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Electrocardiogram | Eyes | Heart | Hypertension | Internal Medicine | Overactive Bladder | Overactive Bladder Syndrome | Study | VESIcare